Sticky Nanoparticles Fight Skin Cancer
Using bioadhesive nanoparticles from the laboratory of Dr. W. Mark Saltzman, Dr. Michael Girardi and his team collaborated with Dr. Saltzman and loaded them with a one-two punch of chemotherapy plus immunotherapy to study its impact in skin cancer. The results may have significant impact for how skin cancer tumors are treated.
Colorectal Cancer and Women
Colon cancer has been undergoing a similar subdivision. Researchers have known for years that colorectal cancer is the third most common cancer diagnosis in the United States and the second leading cause of cancer-related deaths. The National Cancer Institute estimates 149,500 new cases in 2021 and 53,000 deaths.
Scientists Unravel Mystery of Sex Disparities in COVID-19 Outcomes
"Age and sex are where immunological changes intersect,” says Akiko Iwasaki, PhD. Over the past year, Iwasaki and her colleagues from around the globe have compiled a rich literature of research that reveals in detail these and other factors that make the virus more lethal for men.Source: YaleNews
Understanding Immune System Blunders in Response to the Coronavirus
Genetics, gender, and even botched timing on the part of the immune response all appear important in the development of COVID-19. Akiko Iwasaki, PhD, is leading research to help us better predict who is likely to sail through a bout with COVID-19 and who may need targeted lifesaving care.
Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Yale Cancer Center Researchers Show Adding Radiation After Immunotherapy Improves Survival Time for Patients with Advanced Lung Cancer
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
Bristol-Myers Squibb's Opdivo Shows 5-Year Survival Benefit in Lung Cancer
Bristol-Myers Squibb released the pooled efficacy and safety results from its Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced non-small cell lung cancer (NSCLC).Source: BioSpace
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.